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We have shown that approximately 40% of breast cancer patients
have an enhanced sensitivity to the chromosome-damaging effects
of ionizing radiation, compared with 5–10% of normal healthy
controls, when their lymphocytes are irradiated in vitro in the G2
phase of the cell cycle (Scott et al, 1994, 1999). This elevated
radiosensitivity has now been confirmed in 3 independent studies
(Parshad et al, 1996; Patel et al, 1997; Terzoudi et al, 2000). Since
G2 radiosensitivity is a feature of many inherited cancer-prone
conditions such as ataxia-telangiectasia, Li-Fraumeni syndrome
and hereditary retinoblastoma (reviewed in Scott et al, 1999), we
proposed that G2 sensitive breast cancer cases had an inherited
predisposition to cancer, mediated through low penetrance genes,
in contrast to the highly expressed genes BRCA1,  BRCA2 and
TP53, which confer a strong family history and account for less
than 5% of all cases (Goldgar et al, 1996; Ford et al, 1998). There
is good epidemiological evidence for the existence of low pene-
trance predisposition in a substantial proportion of patients (Teare
et al, 1994; Lichtenstein et al, 2000; Peto and Mack, 2000). 
We have used several approaches to test the hypothesis that G2
chromosomal radiosensitivity is a marker for low penetrance
predisposition to breast and other common cancers. One approach
was to investigate the G2 response of blood relatives of breast
cancer patients, from which we found good evidence of heri-
tability of radiosensitivity attributable to the Mendelian segrega-
tion of one or two genes in each family (Roberts et al, 1999; Scott
et al, 2000). In parallel with these family studies, and reported
here, we tested patients with chronic diseases other than cancer, to
determine whether or not the enhanced lymphocyte sensitivity of
breast cancer cases could simply be a consequence of their illness.
Also, we tested patients with colorectal cancer, for which there is
good evidence of low penetrance predisposition (Cannon-Albright
et al, 1988; Lichtenstein et al, 2000) in addition to the high cancer
risk associated with rare mutations in the APC and mismatch
repair genes (Farrington and Dunlop, 1996). As a further test of the
specificity of G2 sensitivity for inherited predisposition, we inves-
tigated the response of patients with cancers for which there is
evidence of a strong environmental aetiology; namely cervical
cancer, linked to infection with the human papilloma virus (Munoz
and Bosch, 1992) and lung cancer, strongly associated with
tobacco smoking (reviewed by Levi, 1999). 
MATERIALS AND METHODS 
Donors 
We have tested normal healthy controls (n = 66), patients with
benign (non-cancerous) chronic diseases (34), a group of breast
cancer patients (31) to compare with our previous cases, and
patients with cervix (27) colorectal (37) or lung (35) cancer. 
Further details of the participants are given in Table 1. The
normal donors comprised staff from this Institute or members of
the general public. The patients with benign disease had either
diabetes mellitus or chronic lung disease that was not malignant
(e.g. chronic obstructive airways disease, cryptogenic fibrosing
alveolitis, bronchiectasis) Those with cancer were patients from
the Christie Hospital NHS Trust and were tested before they
received radio- or chemotherapy. 
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All of the blood samples were from local donors. This was an
important feature of the G2 testing because we have previously
found poorer reproducibility in the assay from samples received
from distant sources and transported by courier (Scott et al, 1999). 
The G2 assay 
Full details are given in Scott et al (1999). Briefly, whole blood
cultures were set up in pre-warmed (37˚C) and pre-gassed (5%
CO2/95% air) medium. One hour later, lymphocytes were stimu-
lated with phytohaemagglutinin (PHA) and cultured for 70 h, at
which time the culture medium was replaced, without centrifuga-
tion, with fresh medium. Cells were irradiated (or mock irradiated)
at 72 h with 0.5 Gy 300 kV X-rays, colcemid was added 30 min
later and at 90 min after irradiation culture vessels were plunged
into ice chippings. Subsequent centrifugation, hypotonic treatment
and fixation was carried out at 4˚C. From 1 h before irradiation to
the time of harvesting, cultures were kept at 37˚C. 
Metaphase preparations were made with standard procedures
and Giemsa stained. Slides were randomized and coded for
analysis and 50 metaphases were scored from both irradiated and
control samples. The low frequency of aberrations in control
samples was substracted from that in irradiated samples to give the
induced yield. The majority of aberrations were chromatid breaks
and gaps that were greater than the width of the chromatid. Smaller
achromatic lesions (gaps) were ignored (Sanford et al, 1989). 
The proportion of blood cultures that yielded 50 analysable
metaphases was less than in our previous studies (Scott et al, 1998,
1999; Roberts et al, 1999). For normal donors we had a 
75% success rate (Table 1) compared with >95% previously. The
success rate for patients with benign or malignant disease varied
from 38% for lung cancers to 80% for cervix cancers (Table 1).
There are several possible reasons, including the limited previous
experience in cytogenetic procedures of the staff involved in labo-
ratory aspects of this study. In addition, in contrast to our previous
studies on breast cancer cases who were relatively healthy at the
time of diagnosis and testing, many patients in this series were in
more advanced stages of malignancy, often with co-morbid
disease, particularly the lung and colorectal cases. Such morbidity
is known to reduce the response of lymphocytes to PHA (Han and
Takita, 1972; Catalona et al, 1973). Our interpretation of the
results presented in this paper assumes that the degree of chromo-
somal radiosensitivity of an individual is not related to the likeli-
hood of successful culturing of their lymphocytes. 
Statistical methods 
Assay reproducibility was assessed using one-way analysis of vari-
ance to give values for inter-and intra-individual variability. Non-
parametric Mann–Whitney U and Kruskall–Wallis tests were used to
compare the patients with normals. Fisher’s exact tests were used in
comparisons of proportions of sensitive individuals. Correlations
between parameters were assessed using Spearman’s correlation
coefficients. A significance level of 0.05 was used throughout. 
RESULTS 
Numbers of successful assays, and ages and sexes of participants
are given in Table 1. 
Normal donors 
Results were obtained on 66 normals, 41 tested once, 25 tested on
2–6 occasions, giving a total of 112 successful tests. 
The mean spontaneous aberration yield was 1.4 ± 1.4 aberra-
tions/100 cells (Table 2), similar to our previous estimate of
1.8 ± 1.9 for 105 normals (Scott et al, 1999). 
The mean induced frequency of aberrations was 85.8 ± 10.8 per
100 cells (range 64–118, Figure 1), slightly lower than our
previous value of 97 ± 15 (range 75–163; Scott et al, 1999). This is
probably because different microscopists were involved in these
studies and reflects small differences in scoring criteria. The repeat
assays on 25 donors allowed an estimate of intra-individual
Table 1 Characteristics of participants and culture success rate 
Group Number of successful cases Male/female Mean age ± SD (range) Total number of samples Success rate (%) 
Normals 66a 22/44 38 ± 11 (20–61) 150 75 
Benign disease 34 18/16 60 ± 15 (21–81) 57 60 
Breast 31 31 56 ± 9 (36–79) 40 78 
Cervix 27 27 59 ± 16 (33–83) 34 80 
Colorectal 37 22/15 63 ± 11 (32–86) 57 65 
Lung 35 24/11 69 ± 9 (50–85) 92 38 
aSeveral repeats on 25 donors giving a total of 112 successful samples (see text). 
Table 2 Aberration yields in the various groups compared with normals 
Group Number Mean spontaneous  Significancea (P) % sensitive Significanceb (P) Mean induced  Significancec (P) 
yield ± SD yield ± SD
Normals 66 1.4 ± 1.4 – 9 – 85.8 ± 10.8 – 
Benign 34 0.7 ± 1.5 0.001 12 0.73 85.8 ± 13.7 0.90 
Breast 31 0.8 ± 1.0 0.028 39 0.001 96.5 ± 23.9 0.042 
Cervix 27 1.4 ± 1.5 0.91 11 0.72 84.6 ± 13.9 0.82 
Colorectal 37 1.3 ± 1.5 0.50 30 0.011 91.5 ± 18.4 0.26 
Lung 35 1.3 ± 1.5 0.80 23 0.072 92.0 ± 14.6 0.044 
aComparison of spontaneous yields with normals. bComparison of % sensitive with normals. cComparison of induced yields with normals. 894 K Baria et al 
British Journal of Cancer (2001) 84(7), 892–896 © 2001 Cancer Research Campaign
variance (assay reproducibility) which gave a coefficient of varia-
tion (CV) of 10.3% compared with a CV of 15.1% for inter-
individual differences between donors. This indicated a significant
difference between donors (P = 0.004) as we have previously
demonstrated (Scott et al, 1999). There was no significant influ-
ence of age (r = 0.11, P = 0.39) or sex (P = 0.96) on induced yields,
as reported earlier (Scott et al, 1999). 
Patients 
None of the patient groups had spontaneous aberration frequen-
cies that were above the normals. In fact, the yields in the breast
cancer cases and benign disease group were less than in normals
(Table 2). We previously found no difference between 135
breast cancer patients and 105 normals (Scott et al, 1999). The
lower yields in the benign group in this study is probably a
chance finding, reflecting the relatively small number of cases
tested. 
Radiation-induced aberration frequencies are given in Table 2
and in Figures 1–2. For none of the patient groups was there any
significant influence of age or sex on induced aberration frequen-
cies. 
Only for breast, colorectal and lung cancer patients were mean
induced aberration yields higher than in normals, but only for breast
cases was this increase statistically significant (Table 2). A better
method of comparing patients with normals is to express the results
in terms of the proportion of sensitive/non-sensitive cases using the
90th percentile of normals as the cutoff value. This follows from our
previous studies of the heritability of G2 sensitivity in which we
found that the distribution of G2 values was multimodal and that the
use of the 90th percentile cutoff distinguished well between normal
individuals and those carrying putative radiosensitizing genes
(Roberts et al, 1999). In the present study this cutoff value was at
100 aberrations/100 cells (Figure 1). This value actually gave a
sensitive proportion of 9% (6/66), rather than exactly 10%, because
the yields for several normals fell exactly at the cut-off point. The
proportion of sensitive cases was significantly higher for breast
(39%) and colorectal (30%) cancer patients (Table 2, Figures 1 and
2). For lung cancer patients, 23% were sensitive (Figure 2), but this
increase did not reach statistical significance (P = 0.07). Patients
with benign disease or cervix cancer had sensitive proportions that
were very similar to normals (Fig. 1). 
DISCUSSION 
Our results are consistent with the hypothesis that elevated G2
lymphocyte chromosomal radiosensitivity is a marker of low pene-
trance predisposition to common cancers. 
Our observation that patients with diabetes or chronic non-
malignant lung disease show a normal response makes it less
likely that enhanced sensitivity in the assay is simply a conse-
quence of morbidity, as does our demonstration that the mean
sensitivity of healthy blood relatives of breast cancer patients is
greater than that of normals (Roberts et al, 1999). However,
patients with other benign diseases should be tested to further
explore this possibility. 
We have confirmed our earlier observations (Scott et al, 1994,
1999) that approximately 40% of breast cancer patients are 
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Figure 1 Yields of radiation-induced aberrations in normal donors and in
patients with non-malignant disease, breast carcinoma and cervical
carcinoma. Repeat tests were performed on 25 normals (2–6 repeats), giving
a total of 112 samples. The vertical solid line indicates the cut-off point
between a normal and a sensitive response. The percentage of sensitive
individuals is given in brackets 
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Figure 2 As for Figure 1 but for normals, colorectal carcinoma and lung
carcinoma patients Chromosomal radiosensitivity as a marker of predisposition to common cancers? 895
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G2-sensitive. The elevated sensitivity of breast cancer patients is
now well established, having been demonstrated in 3 independent
studies (see earlier). Further epidemiological evidence that a high
proportion of breast cancers arise in genetically predisposed indi-
viduals has been provided by studies of breast cancer in twins
(Peto and Mack, 2000). 
Our hypothesis predicts that the enhanced G2 sensitivity that we
observed in 30% of colorectal cancer cases is indicative of low-
penetrance predisposition. Family studies by Cannon-Albright 
et al (1988) strongly support the existence of such genes and led to
their suggestion that inherited susceptibility is involved in a high
proportion of colorectal cancers. From analyses of cancers in twins
in Scandinavia, Lichtenstein et al (2000) conclude that 35% of the
risk of colorectal cancer can be explained by heritable factors. 
The lack of a statistically significant increase in the proportion
of G2-sensitive lung cancer cases compared with normals is
consistent with the knowledge that cancer at this site has a
predominantly environmental aetiology and is largely a conse-
quence of tobacco useage. However, there are also indications of
genetic predisposition to lung cancer (reviewed by Sellers, 1996;
Lichtenstein et al, 2000) with some evidence that smoking-related
cases are associated with polymorphisms in CYP2 genes involved
in the metabolic activation of procarcinogens in cigarette smoke
(Uematsu et al, 1991). If differences in carcinogen metabolism
underlie susceptibility to lung cancer, these differences would not
be detected by the G2 assay. The increase in proportion of sensitive
lung cancer cases, although non-significant, may indicate a reduced
DNA repair capacity in some patients. Rudiger et al (1989) found
that levels of the DNA repair enzyme 06-methylguanine-DNA-
methyltransferase were, on average, lower in cells of lung cancer
patients than in healthy controls. However, this enzyme is
involved in the repair of damage from alkylating agents and there
is no reason to assume that it would influence response to ionizing
radiation. 
Patients with colorectal or lung cancer show enhanced sensi-
tivity to the chromosome-damaging effects of bleomycin in G2
lymphocytes (Hsu et al, 1989). However, breast cancer patients
were similar to normals, so the response of G2 cells to bleomycin
cannot be regarded as a surrogate for G2 radiation sensitivity. 
Although there is evidence that risk of cervical cancer is associ-
ated with specific histocompatibility antigens which confer
reduced immune surveillance of human papillomavirus (Stern,
1996) such immune deficiency would not be detected with our
radiosensitivity assay and this is reflected in our results. The twin
studies of Lichtenstein et al (2000) did not show any significant
inherited component in the risk of cervical cancer. 
Evidence that a particular type of cancer is caused by specific
environmental exposure does not preclude an inherited component
of risk which would be detected by the G2 assay. For example, we
have recently shown in head and neck cancers, for which there is
strong evidence of causation by tobacco and alcohol consumption,
there is increased G2 sensitivity in early onset cases (Papworth 
et al, 2001). 
Recently, Terzoudi et al (2000) reported that the average G2
radiosensitivity of 185 patients with various cancers was signific-
antly greater than that of 25 normals. The patients included 14
with lung cancer and 20 with cervix cancer, both groups having
elevated mean yields of aberrations compared with the normals.
However, the statistical significance of these increased yields was
not given. Importantly, the range of yields for the normals, and for
the lung and cervix cancer patients, was 2–3 times greater than we
have observed so the numbers of individuals tested by Terzoudi 
et al may be insufficient to establish whether or not there is a clear
enhancement in these patients. 
Studies of heritability of G2 sensitivity of the type that we have
undertaken for breast cancer patients would help to clarify the
predictive value of the assay for cancer predisposition at other
sites. Where heritability can be demonstrated, this could lead to
the identification of the predisposing genes by genetic linkage
analysis (see Roberts et al, 1999). 
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